CREST Background Study Conception and Timeline
The organizational work on the CREST project was initiated in 1996 by the project's executive committee, which first published on its concept, rationale, and design in 1997. 1 The experiential basis for the trial was chiefly 2 small stenting registries in high-surgical-risk, symptomatic patients totaling Ϸ200 procedures and reporting mortality rates of up to 3% and stroke rates of between 3% and 6%. 2, 3 The CREST executive committee recognized the novel nature and early stage of the technique, and in accordance with the tenets of clinical equipoise, as well as to provide reassurance to randomizing physicians that a reasonable safety of carotid artery stenting (CAS) had been established at an operator level and across sites, a rigorous credentialing phase was detailed for all participating centers. One of the stated secondary goals of CREST, to describe this experience in the lead-in phase of CREST, has been completed and published elsewhere. 4 Although a 3-year enrollment period was originally anticipated for the main randomized trial, based on 50 sites recruiting 20 symptomatic patients per year, CREST ultimately required nearly 8 years and 120 centers to com-plete enrollment. Some of this delay can be ascribed to the pace of center certification given the aforementioned CAS credentialing requirements and the lack of qualified operators early in the course of the trial; although there were 47 centers selected to participate in CREST as of June 2001 (6 months after the initial patient was randomized), only 8 centers were approved to enroll lead-in CAS patients, and only a single center was qualified to randomize patients. 5
National Institutes of Health Analysis Framework
CREST received its operational funding from the National Institutes of Health, National Institute of Neurological Disorders and Stroke (NIH-NINDS) in January 1999 through an investigator-originated (R01) grant (NS 38384), which was subsequently converted to a cooperative agreement (U01) for the duration of the trial. Device support was provided by Guidant (now Abbott Vascular, Santa Clara, CA). Before trial initiation, the Healthcare Financing Administration was required to modify a longstanding national noncoverage policy for carotid angioplasty to allow reimbursement for the hospital and physician costs of the trial for participating Medicare and Medicaid beneficiaries, which became effective in July 2001. The primary NIH analysis has been published, 6 along with several of the secondary analyses. [7] [8] [9] Objectives, end points, and analyses for the NIH evaluation are compared below to those specified by the FDA for the post-market approval (PMA) analysis (see Methodological Differences Between NIH and PMA Analyses).
FDA Binding Agreement History
In 1997, during the initial CREST application review, NIH-NINDS recommended the use of a single stent device. In May 1999, Guidant Corporation (now Abbott Vascular), the manufacturer of the ACCULINK Carotid Stent System, agreed to participate in CREST as the sole supplier of the study device and initiated formal discussions with the FDA to support an indication for patients at standard risk for adverse events from CEA. These efforts resulted in a binding agreement between FDA and Guidant in July 1999. In this FDA binding agree-ment, the primary end point for device analysis was defined as stroke, myocardial infarction (MI), or death within 30 days, plus ipsilateral stroke to 1 year, which differed from the NIH-NINDS primary end-point follow-up of 4 years. To support product approval, the FDA requested a hypothesis test of noninferiority between the 2 procedures for the primary end-point analysis, with a margin of 2.6%. Importantly, this analysis was predefined as distinct from the NIH-NINDS superiority analysis and was in keeping with predicate and subsequent carotid stent device trials in terms of noninferiority hypothesis testing formulation, safety and effectiveness end-point definitions, and temporal duration of assessment. 10 Although the potential for disparate outcomes between the NIH and FDA analyses was contemplated by the CREST executive committee, this probability was calculated to be Ͻ1/1000. Nevertheless, because the study had 2 separate goals-to assess differences in long-term efficacy of CEA versus CAS as treatment strategies (NIH-NINDS) and to evaluate the safety and efficacy of a stent system compared with CEA (FDA)-distinct data analyses were required, which created considerable complexity.
As industry funder, Guidant was initially responsible for holding the investigational device exemption. In February 2003, the investigational device exemption was transferred from Guidant to the principal investigator, Robert Hobson, MD (deceased, 2007) , and then to Thomas Brott, MD, to streamline communications among the supervisory authorities within the trial. 5 Guidant, and later Abbott Vascular, funded the transfer of the investigational device exemption responsibilities to the principal investigator, the monitoring of the trial by a clinical research organization, and expenses related to managing the trial, data management support, and incentives for sites to complete case report form data entry in a timely manner.
CREST initially included symptomatic patients with an ipsilateral Ն50% carotid bifurcation stenosis. Five years after the initiation of trial enrollment, the CREST protocol was modified to include asymptomatic subjects (reflecting new data from Europe regarding the efficacy of revascularizing asymptomatic patients, 11 as well as to accelerate recruitment), which led to a revised binding agreement with the FDA in November 2005. The new agreement prespecified the nature of the primary and secondary analyses. In the 2005 FDA binding agreement, the power analysis was predicated on the assumption that enrollment would include Ϸ50% asymptomatic subjects. This had the effect of increasing the statistical power from 80% to 82%, given the same margin of noninferiority (2.6%), but with lower assumed event rates for both CAS and CEA in the now-mixed (symptomatic and asymptomatic) population.
FDA Prespecified Analyses
The FDA binding agreement planned for the analyses to be conducted at the completion of the trial (Table 1) . Per FDA regulations, Abbott Vascular generated a Statistical and Analytic Plan that incorporated in great detail all analyses requested by the FDA and submitted it to that agency for approval in advance of data unblinding. During the course of CREST, all trial data were received, centralized, and processed at the University of Alabama at Birmingham.
In addition to the primary end-point noninferiority hypothesis test, the CREST PMA analysis included 5 other prespecified noninferiority hypothesis tests to be conducted on (1) symptomatic patients; (2) asymptomatic patients; (3) nonoctogenarian patients; (4) rates of death, stroke, or MI (DSMI); and (5) primary end-point rates up to 4 years. No hypothesis of noninferiority was prespecified for octogenarian patients. Although octogenarians were included in the randomization phase of CREST, published outcome data in CEA were sparse (eg, octogenarians were excluded from landmark randomized CEA studies, including the North American Symptomatic Carotid Endarterectomy Trial and the Asymptomatic Carotid Atherosclerosis Study) and outcomes in CAS patients identified octogenarian status as a predictor of adverse outcomes, 12 which raised concerns regarding the lack of clinical equipoise between CAS and CEA for this patient population in CREST. Therefore, before data unblinding, a prespecified noninferiority analysis for nonoctogenarians was agreed on with the FDA and added to the Statistical and Analytic Plan.
Populations to Be Studied in the FDA Analysis
Before data were unblinded, the FDA requested that the primary end-point analysis be conducted on 4 prespecified analysis populations: Intention to treat, as treated, modified as treated, and per protocol. Additionally, a propensity score adjusted per-protocol analysis was required. The prespecified study populations, as defined in the Statistical and Analytic Plan and agreed on with FDA, are summarized in the online-only Data Supplement ( Figure I ).
Regulatory Perspective on Study Device

Preexisting FDA Approval and Experience for ACCULINK Carotid Stent System
Since 2002, the device has had regulatory approval in Europe and has been commercialized in Ͼ85 countries, with no 13 Guidant previously submitted the PMA to the FDA for the device system tested, which consisted of the ACCULINK carotid stent and the ACCUNET embolic filter. In August 2004, the FDA approved the ACCULINK Carotid Stent System for CAS in patients with severe carotid stenosis at high risk for adverse events from CEA, both with and without prior neurological symptoms. The CREST panel deliberations did not include this high-risk population; therefore, the outcome of the panel vote would not affect the existing indications for use 14 in high-risk patients.
As a condition of the initial 2004 approval, the FDA required Guidant to conduct a postmarket study (ie, CAP-TURE [Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events]) intended to assess both the incidence of rare and unanticipated events not captured in the pivotal study (ARCHeR, enrollment completed in 2002) and the adequacy of technology transfer from the trial setting to the clinical environment via physician training programs. The outcomes of CAPTURE (enrollment completed in 2006) and the subsequent study, CAPTURE 2 (performed to provide Centers for Medicare and Medicaid Services coverage with evidence development; enrollment completed in 2010) have been extensively published elsewhere. 12, [15] [16] [17] [18] Since conducting ARCHeR, rates of 30-day DSMI with the ACCULINK/ ACCUNET system have been noticeably reduced; specifically, 30-day DSMI rates for ARCHeR, CAPTURE, and CAPTURE 2 were 8.3%, 6.1%, and 3.5%, respectively. These studies, representing Ͼ180 sites and 450 operators in the United States, established the safety and effectiveness of the device for patients at high surgical risk in nontrial clinical settings. The clinical outcomes achieved in these postmarket studies of CAS in patients at high surgical risk met the American Heart Association guidelines threshold of adverse events set for CEA in patients at standard surgical risk; these AHA guideline thresholds were derived from outcomes of prior CEA trials in nonoctogenarian, standardrisk surgical patients.
Current Application for a PMA-s
In submitting the CREST PMA-s, the funder sought an extension to the current approved use of the ACCULINK Carotid Stent System (ie, in patients with carotid stenosis considered at high risk for adverse events from CEA) to include patients with carotid stenosis considered at standard risk, regardless of symptomatic status. The proposed changes to the indications for use are consistent with the population studied in CREST, specifically symptomatic standard-risk patients with carotid artery stenosis Ͼ70% stenosis by ultrasound or Ͼ50% stenosis by angiogram and asymptomatic standard-risk patients with Ͼ70% stenosis by ultrasound or Ͼ60% stenosis by angiogram.
Methodological Differences Between NIH and PMA Analyses
The results of the NIH analysis of the CREST data were published in the New England Journal of Medicine in 2010. 6 Although different in objectives and methodologies, these 2 analyses were nevertheless shown to be consistent and complementary ( Table 2 ). The objectives of the PMA analyses are device specific and meant to support FDA assessment and possible approval of the device, whereas the objectives of the NIH analyses are to provide academic and scientific evaluation of 2 carotid revascularization strategies. Because the mandate of the FDA is to provide reasonable assurance of safety and effectiveness of the device, these principles guide the statistical methodologies and analytic plan for the PMA. The PMA analyses used a noninferiority hypothesis test performed on a primary end point at 1 year, using the per-protocol population, whereas the NIH analyses used a superiority hypothesis test performed on a primary end point at 4 years, using the intent-to-treat population. The PMA analyses included an adverse event count that began on the day of procedure, whereas the NIH analyses tallied adverse events beginning on the day of randomization. Another key difference was that all adjudicated primary end points were used in the PMA analyses; for MI was defined as all adjudicated MIs determined by an independent Myocardial Infarction Adjudication Committee to be "possible" or "definite" *All patients as randomized. †All patients as randomized minus those with a primary end point event before the procedure.
example, the PMA analyses included all MIs adjudicated as "possible" and "definite." This strict adjudication ensured the most conservative approach, in keeping with the FDA precedent for determining device safety. In contrast, the NIH analysis used the MI protocol definition from amendment V, in which biomarker changes were required to define an MI in addition to either clinical symptoms or ECG changes consistent with ischemia. As a result, there were 20 fewer MIs reported in the NIH analyses than in the PMA analyses (12 for CEA and 8 for CAS). Despite all the differences outlined above, the 2 analyses yielded similar results. The noninferiority hypothesis test was performed post hoc to the NIH primary end-point outcomes, which yielded results that were fundamentally the same as those achieved in the NIH analysis, with the primary end point meeting the noninferiority criteria.
For a more detailed description of the distinct objectives of the 2 parallel primary end-point analyses (ie, NIH and PMA) and respective secondary and post hoc analyses, as well as the associated differences in end-point definitions, analysis populations, and statistical methodologies, please refer to the online-only Data Supplement Addendum to this panel report. Figure 1 is the graphical representation of the primary end point of CREST PMA analyses (ie, composite of all death, any stroke, or MI to 30 days plus ipsilateral stroke from 31-365 days) in the per-protocol analysis population. There is an absolute observed difference of 0.5% between the therapies, which, along with the accompanying 1-sided 95% confidence limit of 2.26%, is within the 2.6% margin of noninferiority ( Figure 1A) . Thus, CAS was demonstrated to be not inferior to CEA in standard-risk patients. In addition, every other prespecified analysis performed on the analysis populations consistently satisfied the noninferiority criteria ( Figure 1B ) for the stent system, therefore further supporting the robustness of the conclusion and interpretation.
PMA Analysis Results
Prespecified Primary End-Point Analyses
Periprocedural Primary End-Point Outcome Measures
Rates of the periprocedural component of the composite end point (DSMI at 30 days) did not differ significantly for patients undergoing CAS (5.8%; 95% CI, 4.5% to 7.3%) or CEA (5.1%; 95% CI, 3.9% to 6.5%) and met the prespecified noninferiority hypothesis demonstrating that CAS was noninferior to CEA ( Table 3 ). Rates of death and major stroke were very low compared with results from prior large randomized trials and were not significantly different between therapies. Minor strokes occurred more frequently in the CAS arm (3.2%; 95% CI, 2.2% to 4.4%) than in the CEA arm (1.5%; 95% CI, 0.9% to 2.4%). MI occurred more frequently in the CEA group (3.4%; 95% CI, 1.2% to 2.9%) than in the CAS arm (2.0%; 95% CI, 2.4% to 4.6%) and generally balanced the outcome event totals, which resulted in the equivalent composite end-point outcomes between groups for DSMI. The probability values listed in Table 3 are for descriptive purposes only, because CREST was neither designed nor powered to draw statistical inference in comparisons of components of the primary end point. No adjustments were made for multiple comparisons. deal of experience, previously not available, was obtained by operators outside of CREST, roughly coincident with the addition of asymptomatic patients to CREST enrollment. In addition, the rates of 30-day DSMI in both FDA device approval and postmarket studies were observed to be declining at a significant pace.
Post Hoc Analysis of the Temporal Trends of End-Point Outcomes
With the non-CREST CAS case load increasing in the United States and the documented rates of complications associated with CAS decreasing, it was reasonable to query the CREST outcomes to assess any in-trial effects of these external factors; an analysis by year was therefore conducted. Given the slow pace of enrollment early in the trial, the first 4 years were grouped together in a single category (ie Figure  2A ). The initial bump in event rates in 2005 may have been related to the sharp increase in new sites and CAS operators added to an already highly experienced initial group. The subsequent decline in rates may be the result of experience acquired by these newer operators (largely outside of CREST) or to the influence of more appropriate case selection, which for CAS was still evolving during the decade of CREST.
The symptomatic subgroup was likewise subjected to this post hoc analysis to determine whether the temporal effect on the composite of death and any stroke over time could be observed independent of the potential impact of asymptomatic patients on lowering event rates ( Figure 2B ). This analysis yielded different event rates but a similar trend; after an initial increase in event rates from 4.4% in the first period to 9.0% in 2005, there was a steady decline from 8.5% in 2006 to 4.2% in 2007 and finally to 2.6% in 2008. These findings confirm that the decline in event rates observed between 2006 and 2008 in CREST was not caused by the addition of asymptomatic patients in 2005 but was more likely related to the overall gain of experience in CAS both within and outside the trial after device approval in this country.
Another post hoc analysis conducted to determine the change in rate of the composite of death or major stroke yielded similar results. After an initial plateau in event rates at 2.5% in the first period and in 2005, there was a steady decline to 0.7% in 2006, 0% in 2007, and 0.6% in 2008 ( Figure 2C ). In the symptomatic subgroup, the effect was even more pronounced ( Figure 2D ). The initial increase in event rates from 2.5% in the first period to 3.6% in 2005 was followed by a sharp decline to 0.8% in 2006 and 0% in 2007 and 2008. Of note, there was not a single death or major stroke in symptomatic patients undergoing CAS in the second half of CREST. No change in event rates over time was observed in a similar temporal analysis of CEA outcomes. A comparison of baseline demographics between CAS and CEA in the second half of CREST did not show any major imbalance between arms. The decreasing rates of stroke and death for CAS over time and the similar rates of death and major stroke for CAS and CEA in the second half of the study were among the key findings that led to a conclusion statement by Abbott Vascular that CAS and CEA had balanced outcomes.
Other Prespecified Secondary End Points
Outcomes by Symptomatic Status and Age According to Octogenarian Status
Although the primary composite end-point rates were higher in symptomatic and octogenarian patients than in their asymptomatic and nonoctogenarian counterparts, there was no evidence of a statistically significant difference between CEA and CAS in either subgroup, as depicted in Figure 3 . Two noninferiority hypotheses were also prespecified in the 2005 binding agreement, 1 for symptomatic patients, and 1 for asymptomatic patients. In addition, a noninferiority hypothesis for nonoctogenarian patients was added to the Statistical and Analytic Plan, well in advance of data unblinding. For each of these subgroups (symptomatic, asymptomatic, and nonoctogenarian), CAS demonstrated noninferiority to CEA in outcome rates for the composite end point of periprocedural DSMI plus ipsilateral stroke to 1 year.
Cranial Nerve Injury
Cranial nerve injury is a complication of CEA that tends to resolve in the first few months after surgery. 19, 20 The most common cranial nerves affected are V, VII, IX, X, and XII. The symptoms of cranial nerve injury can include lower jaw numbness, lower lip weakness, difficulty swallowing, hoarseness caused by vocal cord paralysis, and difficulty with speech because of tongue deviation. There were no cranial nerve injuries experienced in the CAS arm of CREST in the per-protocol population (online-only Data Supplement Table  I ). For the CEA arm, there was a 5.3% postoperative incidence of cranial nerve injury, which was reduced to 2.1% at 6 months. Of note, the majority of these (80%) involved a motor deficit.
Access Site Complications Requiring Treatment
Access site complications arising from either CEA or CAS are important secondary outcomes. For CAS, a bleeding complication can result in a retroperitoneal accumulation of blood and is potentially life-threatening. For CEA, bleeding at the surgical site is also potentially serious and may require reoperation to prevent or treat airway obstruction. In CREST, access site complications were significantly more frequent in the CEA group, with Ϸ3 times the occurrence as with CAS (3.7% versus 1.1%, Pϭ0.0001). Bleeding that required reoperation was Ͼ8 times more frequent after CEA (nϭ17) than after CAS (nϭ2; online-only Data Supplement Figure II) .
Long-Term Outcomes and Predictors of Mortality
CAS and CEA did not differ in terms of long-term ipsilateral stroke prevention or requirement for target-lesion revascularization over the 4-year period (online-only Data Supplement Figures IIIA and IIIB) . All-cause mortality was also comparable in the 2 treatment groups, as shown in the Kaplan-Meier 4-year plot (online-only Data Supplement Figure IIIC) .
For periprocedural (ie, Ͻ30 days of procedure) stroke or MI, the presence of tobacco use, diabetes, ischemic heart disease/congestive heart failure, male sex, and advanced age were all associated with an increased risk of postprocedure death. The results of the Cox regression model for prediction of long-term mortality are shown in online-only Data Supplement Table II . Importantly, the 2 strongest predictors of mortality were stroke (hazard ratio [HR], 2.49; Pϭ0.0011) and MI (HR, 2.14; Pϭ0.0079). These results were consistent with the survival analysis that compared patients with periprocedural stroke or patients with periprocedural MI to patients without either periprocedural stroke or MI, defined as the control group ( Figure 4A) ; however, a survival analysis comparing minor stroke with the 2 other subgroups showed that there was no impact of minor stroke on mortality ( Figure  4B ). These survival curves were important evidence for the panel to review considering the differential in event rates between CAS and CEA for MI and minor stroke (ie, twice as many periprocedural minor strokes after CAS than after CEA, and twice as many MIs after CEA than after CAS). In addition, Abbott Vascular presented data relative to the resolution of minor strokes over time ( Figure 5 ) that showed that the vast majority of these events resolved completely and without any deficit at 6 months, as measured by the NIH Stroke Scale or the modified Rankin Scale. The number of patients left with residual deficits from minor strokes was equal or similar in both arms (CAS: nϭ7, CEA: nϭ7 by NIH Stroke Scale; CAS: nϭ9, CEA: nϭ6 by modified Rankin Scale).
Interactions
Subgroup Interaction Analysis
Prespecified interaction analyses using the primary end point and predefined subgroups found no interaction of symptomatic status, age (binary, Ն80 or Ͻ80 years), or sex with treatment outcomes. A post hoc interaction analysis for diabetes also found no evidence of interaction for this clinical variable (online-only Data Supplement Figure IV) .
Age
A closer examination of the comparative outcomes of CAS and CEA in patients by age subgroups is shown in Figure 6A ; in this analysis, primary end-point rates up to 4 years are depicted for 5-year increments on a hazard scale. For patients Ն80 years of age, the HR was 1.01 (Pϭ0.988), which indicates that primary end-point event rates were equivalent for octogenarians undergoing CAS or CEA. HRs stratified by age groups fluctuated and their 95% CI overlapped substantially, which indicates no clear trends.
Because of the apparent advantage for patients Ͻ60 years old who underwent CAS (HRϭ0.39; HR in favor of CAS: 1/0.39ϭ2.56; 95% CI, 0.16 -0.95; Pϭ0.038), the slope of a "best fit" curve (originally used in the CREST NIH analysis published in the New England Journal of Medicine 6 ) may be skewed, resulting in the appearance of a possible disadvantage for older patients undergoing CAS when in fact none exists. Exclusion of the group of patients Ͻ60 years old results in a leveling of the "best fit" line and the disappearance of any clear age effect, consistent with the aforementioned negative test for interaction.
The FDA independently also performed an age interaction analysis, finding a nonsignificant (Pϭ0.20) linear pattern and therefore no evidence of a statistically significant differential outcome by age between CAS and CEA. Later, the FDA confirmed that the original curvilinear pattern was driven by a regression equation that needed to take into account younger patients, in whom CAS was significantly superior to CEA.
Use of Embolic Protection
A total of 24 patients did not receive an embolic protection device: 5 patients were enrolled before the device was available, and 19 others did not have embolic protection devices placed for various reasons. These patients differed from those able to receive embolic protection devices (eg, they were older and more likely to have had symptoms before the procedure), and therefore, their outcomes were subject to selection bias. It is nevertheless noteworthy that there was a 20.8% rate of 30-day DSMI in the 24 patients without embolic protection devices. The exclusion of these patients resulted in an overall 30-day rate of DSMI for CAS patients of 5.3%, which more closely approximates the rate of 5.1% for CEA patients, and a primary end-point rate (6.6%) that was exactly equal for CAS and CEA (P for noninferiority, 0.0080).
Panel Discussion and Vote
At the conclusion of the presentations and public deliberations, the panel was asked by the FDA to vote on 3 questions pertaining to use of the RX ACCULINK Carotid Stent System in patients at standard surgical risk who require carotid revascularization and who meet the criteria specified in the proposed indication:
1. Whether there is reasonable assurance that the system is safe 2. Whether there is reasonable assurance that it is effective 3. Whether the benefits outweigh the risks for use On question 1, the panel voted 6-4-1 (yes, no, or abstained, respectively), agreeing that the data demonstrated that there is reasonable assurance that the RX ACCULINK Carotid Stent System is safe for use in patients requiring carotid revascularization who meet the criteria specified in the proposed indication. Concerns were voiced by panel members regarding the safety of the stenting procedure, given the 2 times higher periprocedural stroke rate for CAS than for CEA; however, these concerns were believed to be mitigated by the improvements in adverse event rates during the second half of the trial (both composite end point and end-point components) in all patients undergoing CAS. There was a greater consensus (8-2-1) on the relative effectiveness of CAS and CEA procedures, with equivalent long-term stroke prevention benefits for both interventions over time. Finally, the panel agreed (7-3-1) that the benefits of the RX ACCULINK Carotid Stent System do outweigh the risks in the standard surgical risk patients as outlined in the proposed indication.
The panel also commented on the postapproval study outlined by the funder as a mechanism for ongoing surveillance of the safety and effectiveness of the stent system in symptomatic and asymptomatic patients and agreed this study should further elucidate any learning curve among participating physicians. The importance of proper training, patient selection, and strict observance of the specified indications was noted.
The industry representative, a nonvoting panel member, commented on the importance of this particular panel vote for the industry as a whole, in light of a very large, randomized controlled trial reaching a prespecified primary end point that was agreed on with the FDA. In a similar vein, an FDA official had previously acknowledged that "to do a device trial that size is extremely tough and arduous." Furthermore, the FDA had determined, in consultation with clinical experts in the field, that (1) the noninferiority design was adequate, and (2) the trial, if successful, would provide robust evidence in support of approval.
Conclusions
In 2307 standard-risk patients with symptomatic and asymptomatic carotid artery disease, CAS demonstrated noninferiority to CEA for the primary composite end point of DSMI within 30 days of the procedure plus ipsilateral stroke from 31 to 365 days in the per-protocol analysis population. However, differences in individual components of the primary end point did occur, with more MIs reported in patients who underwent CEA, and with minor strokes reported more frequently in patients who underwent CAS. A significant number of minor strokes that occurred in CAS patients resolved by 6 months, which resulted in comparable unresolved minor stroke rates in the CAS and CEA arms at the 6-month time point. Survival analysis showed that MIs were associated with early and late mortality, whereas minor strokes were not. The separate and independent analysis of the CREST data using a superiority test hypothesis conducted on the NIH-NINDS intent-to-treat analysis population with 4-year follow-up yielded similar results. 6 The achievement of comparable results from 2 independent analyses lends credibility to the finding that CAS using the ACCULINK/ ACCUNET system is as safe and effective as CEA for standard-risk patients and is especially noteworthy in light of the numerous logistical and regulatory challenges faced by the CREST investigators. In the CREST PMA analysis, a lower primary end-point rate was observed in CAS patients who received the ACCUNET embolic protection system relative to those who did not, which indicates that the use of embolic protection was associated with better outcomes in this study.
There was a significant trend toward lower death and stroke rates in the latter half of the CREST trial, possibly because of improved technical proficiency, operator experience, and patient selection, which may require careful consideration. It is noteworthy that US approval of CAS in late 2004 roughly coincided with this improvement and may have contributed to an increased experience base for CAS outside of CREST and translated to improved outcomes within the trial. The improved CAS outcomes demonstrated over the 8-year course of the CREST trial correlate with the marked improvement in CAS outcomes seen in FDA investigational device exemption trials throughout the decade. This trend supports the hypothesis that increased operator experience and refined case selection should result in further improvement of CAS outcomes relative to CEA. The funder proposed a postapproval study to further investigate the ongoing risk of periprocedural death and stroke in symptomatic and asymptomatic standard risk patients, as well as to provide additional long-term follow-up data in real-world settings.
There was no evidence of a statistically significant age interaction with the primary end point for either intervention. The apparent trend toward worse outcomes in older relative to younger patients undergoing CAS was independently demonstrated by both the funder and the FDA to be an artifact of the best-fit methodology, driven by the better outcomes for CAS in patients Ͻ60 years of age and not by any differences in outcomes for older patients.
The FDA's Circulatory System Devices Advisory Panel reviewed and considered the data and rendered a final vote recommending approval. On the basis of these data and the panel's recommendation, the FDA subsequently granted the ACCULINK Carotid Stent System an extension for its indication to include patients at standard surgical risk, independent of symptomatic status, on May 6, 2011.
